HAWTHORNE, N.Y.--(BUSINESS WIRE)--March 31, 2006--Acorda Therapeutics (Nasdaq:ACOR) today announced its financial results for the fourth quarter and full year ended December 31, 2005. “The launch of Zanaflex Capsules in April 2005 transformed Acorda into a fully-integrated biotechnology company. In 2005, we also received an SPA from the FDA for our Fampridine-SR Phase 3 study in MS, which we initiated. We now have a commercial sales and marketing operation, complementing our strong pipeline and clinical and pre-clinical capabilities,” stated Ron Cohen, M.D., President and CEO. “These accomplishments provided the foundation for the successful completion of our initial public offering in February 2006.”
